Table 2.
Univariate and multivariate overall survival analysis of epidermal growth factor receptor (EGFR) ligands in 399 HNSCC patientsa
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Factorsb | p | HR (95%CI)c | p | HR (95%CI) |
| EGF | 0.008 | 1.635 (1.139–2.348) | 0.002 | 1.776 (1.233–2.559) |
| HBEGF | 0.034 | 1.477 (1.031–2.116) | 0.32 | 1.218 (0.828–1.793) |
| TGFA | 0.20 | 1.583 (0.882–1.806) | ||
| AREG | 0.002 | 1.759 (1.227–2.522) | 0.001 | 1.857 (1.257–2.743) |
| BTC | 0.006 | 1.662 (1.157–2.386) | 0.002 | 1.778 (1.233–2.564) |
| EPGN | 0.23 | 0.802 (0.562–1.145) | ||
| EREG | 0.28 | 1.218 (0.852–1.757) | ||
aLog-rank test was used in univariate analysis and Cox Regression method was used in multivariate analysis
bmRNA expression levels were measured as fragments per kilobase per million mapped reads (FPKM) and median mRNA expression levels were used as discriminators (epidermal growth factor (EGF): 17.88 FPKM; heparin-binding EGF-like growth factor (HB-EGF): 1274 FPKM; transforming growth factor-α (TGFA): 1695 FPKM; amphiregulin (AREG): 658 FPKM; beta-cellulin (BTC): 4 FPKM; epigen (EPGN): 32.5 FPKM; epiregulin (EREG): 350 FPKM), and the groups of patients with lower expression levels were set as reference
cHR, Hazard ratio. 95 % CI, 95 % confidence interval